{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:07:40Z","timestamp":1784297260700,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R33CA267258"],"award-info":[{"award-number":["R33CA267258"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Biomed Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The incidence of autoimmune diseases has increased in Western societies, highlighting the need for novel treatment strategies. Current therapies, including biologics, are limited by high costs, potential adverse effects, and often lack specificity and long-term efficacy. Regulatory T cells (Tregs) are crucial for maintaining immune tolerance and represent a promising target for autoimmune disease therapies. However, current methods for inducing Tregs, such as in vitro cytokine combinations and in vivo antigen-specific approaches, face challenges in stability and effectiveness. This research aims to develop an innovative artificial cell platform to enhance Treg induction for autoimmune disease treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study developed artificial GARP-presenting cells (aGPCs), an innovative artificial cell platform designed to mimic natural cellular functions and enhance Treg induction. We evaluated aGPC efficacy in inducing Tregs both in vitro and in vivo, comparing results with control groups. Treg populations, suppression assay, cytokine profiles (IL-10 and IFN-\u03b3), and biocompatibility were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The current study demonstrates that aGPCs significantly increase the induction of Tregs both in vitro and in vivo compared to control groups. The aGPC-GARP\n                      <jats:sup>+<\/jats:sup>\n                      group notably enhanced Treg populations and increased IL-10 secretion while reducing IFN-\u03b3 levels, indicating effective immune modulation. In vivo experiments confirmed the biocompatibility and efficacy of aGPCs in inducing Tregs in mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that aGPCs could be applied to Treg-based therapies and hold promise for developing antigen-specific treatments for inflammatory disorders and autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10439-026-04278-4","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:46:02Z","timestamp":1784295962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Microfluidic Precision Engineered Artificial GARP Presenting Cells for Regulatory T-Cell Induction"],"prefix":"10.1007","author":[{"given":"Hsiu-Ping","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhanshu","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Hau Lai","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8378-6616","authenticated-orcid":false,"given":"Abraham P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"4278_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.12691\/ijcd-3-4-8","volume":"3","author":"A Lerner","year":"2016","unstructured":"Lerner, A., P. Jeremias, and T. Matthias. The world incidence and prevalence of autoimmune diseases is increasing. Int. J. Celiac Dis. 3:151\u2013155, 2016.","journal-title":"Int. J. Celiac Dis."},{"issue":"3","key":"4278_CR2","first-page":"251","volume":"24","author":"E Rosato","year":"2010","unstructured":"Rosato, E., S. Pisarri, and F. Salsano. Current strategies for the treatment of autoimmune diseases. J. Biol. Regul. Homeost. Agents. 24(3):251\u2013259, 2010.","journal-title":"J. Biol. Regul. Homeost. Agents."},{"key":"4278_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1741-7015-11-88","volume":"11","author":"Z Rosman","year":"2013","unstructured":"Rosman, Z., Y. Shoenfeld, and G. Zandman-Goddard. Biologic therapy for autoimmune diseases: an update. BMC Med. 11:88, 2013. https:\/\/doi.org\/10.1186\/1741-7015-11-88.","journal-title":"BMC Med."},{"issue":"1","key":"4278_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","volume":"181","author":"L Fugger","year":"2020","unstructured":"Fugger, L., L. T. Jensen, and J. Rossjohn. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. Cell. 181(1):63\u201380, 2020. https:\/\/doi.org\/10.1016\/j.cell.2020.03.007.","journal-title":"Cell."},{"key":"4278_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4103\/0253-7613.103235","volume":"44","author":"S Chandrashekara","year":"2012","unstructured":"Chandrashekara, S. The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. Indian J. Pharmacol. 44:665, 2012. https:\/\/doi.org\/10.4103\/0253-7613.103235.","journal-title":"Indian J. Pharmacol."},{"key":"4278_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali, D. A., L. W. Collison, and C. J. Workman. How regulatory T cells work. Nat. Rev. Immunol. 8:523\u2013532, 2008. https:\/\/doi.org\/10.1038\/nri2343.","journal-title":"Nat. Rev. Immunol."},{"key":"4278_CR7","first-page":"131","volume":"46","author":"P Chrob\u00e1k","year":"2003","unstructured":"Chrob\u00e1k, P. Control of T cell responses, tolerance and autoimmunity by regulatory T cells: current concepts. Acta Med. 46:131\u2013137, 2003.","journal-title":"Acta Med."},{"key":"4278_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/trf.16797","volume":"62","author":"T Mamo","year":"2022","unstructured":"Mamo, T., K. L. Hippen, M. L. MacMillan, C. G. Brunstein, J. S. Miller, J. E. Wagner, B. R. Blazar, and D. H. McKenna. Regulatory T cells: a review of manufacturing and clinical utility. Transfusion. 62:904\u2013915, 2022. https:\/\/doi.org\/10.1111\/trf.16797.","journal-title":"Transfusion."},{"key":"4278_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.autrev.2010.08.013","volume":"10","author":"S Langier","year":"2010","unstructured":"Langier, S., K. Sade, and S. Kivity. Regulatory T cells: the suppressor arm of the immune system. Autoimmun. Rev. 10:112\u2013115, 2010. https:\/\/doi.org\/10.1016\/j.autrev.2010.08.013.","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"4278_CR10","first-page":"341","volume":"25","author":"A Dasgupta","year":"2012","unstructured":"Dasgupta, A., and R. Saxena. Regulatory T cells: a review. Natl. Med. J. India. 25(6):341\u2013351, 2012.","journal-title":"Natl. Med. J. India."},{"key":"4278_CR11","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00018-009-0026-2","volume":"66","author":"CJ Workman","year":"2009","unstructured":"Workman, C. J., A. L. Szymczak-Workman, L. W. Collison, M. R. Pillai, and D. A. Vignali. The development and function of regulatory T cells. Cell. Mol. Life Sci. 66:2603\u20132622, 2009. https:\/\/doi.org\/10.1007\/s00018-009-0026-2.","journal-title":"Cell. Mol. Life Sci."},{"key":"4278_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750542","author":"P Grover","year":"2021","unstructured":"Grover, P., P. N. Goel, and M. I. Greene. Regulatory T cells: regulation of identity and function. Front. Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.750542.","journal-title":"Front. Immunol."},{"key":"4278_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1600-065X.2010.00913.x","volume":"236","author":"SP Cobbold","year":"2010","unstructured":"Cobbold, S. P., E. Adams, K. F. Nolan, F. S. Regateiro, and H. Waldmann. Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link. Immunol. Rev. 236:203\u2013218, 2010. https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00913.x.","journal-title":"Immunol. Rev."},{"key":"4278_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2008-11-191197","volume":"114","author":"DJ Chung","year":"2009","unstructured":"Chung, D. J., M. Rossi, E. Romano, J. Ghith, J. Yuan, D. H. Munn, and J. W. Young. Indoleamine 2,3-dioxygenase\u2013expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood. 114:555\u2013563, 2009. https:\/\/doi.org\/10.1182\/blood-2008-11-191197.","journal-title":"Blood."},{"key":"4278_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1615\/critrevimmunol.v26.i4.10","volume":"26","author":"D Kabelitz","year":"2006","unstructured":"Kabelitz, D., D. Wesch, and H.-H. Oberg. Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit. Rev. TM Immunol. 26:291\u2013306, 2006. https:\/\/doi.org\/10.1615\/critrevimmunol.v26.i4.10.","journal-title":"Crit. Rev. TM Immunol."},{"key":"4278_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148474","author":"A Schmidt","year":"2016","unstructured":"Schmidt, A., M. Eriksson, M.-M. Shang, H. Weyd, and J. Tegn\u00e9r. Comparative analysis of protocols to induce human cd4+foxp3+ regulatory T cells by combinations of IL-2, TGF-beta, retinoic acid, rapamycin and butyrate. PLoS One. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0148474.","journal-title":"PLoS One."},{"key":"4278_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00654","author":"AL Perdigoto","year":"2016","unstructured":"Perdigoto, A. L., L. Chatenoud, J. A. Bluestone, and K. C. Herold. Inducing and administering Tregs to treat human disease. Front. Immunol. 2016. https:\/\/doi.org\/10.3389\/fimmu.2015.00654.","journal-title":"Front. Immunol."},{"key":"4278_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61737-979-6_11","author":"C Daniel","year":"2011","unstructured":"Daniel, C., H. Ploegh, and H. von Boehmer. Antigen-specific induction of regulatory T cells in vivo and in vitro. Methods Mol. Biol. 2011. https:\/\/doi.org\/10.1007\/978-1-61737-979-6_11.","journal-title":"Methods Mol. Biol."},{"key":"4278_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.it.2016.08.012","volume":"37","author":"M Kanamori","year":"2016","unstructured":"Kanamori, M., H. Nakatsukasa, M. Okada, Q. Lu, and A. Yoshimura. Induced regulatory T cells: their development, stability, and applications. Trends Immunol. 37:803\u2013811, 2016. https:\/\/doi.org\/10.1016\/j.it.2016.08.012.","journal-title":"Trends Immunol."},{"key":"4278_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.681062","author":"DA Horwitz","year":"2021","unstructured":"Horwitz, D. A., S. Bickerton, and A. La Cava. Strategies to use nanoparticles to generate CD4 and CD8 regulatory T cells for the treatment of SLE and other autoimmune diseases. Front. Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.681062.","journal-title":"Front. Immunol."},{"key":"4278_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.actbio.2020.06.004","volume":"112","author":"KR Rhodes","year":"2020","unstructured":"Rhodes, K. R., R. A. Meyer, J. Wang, S. Y. Tzeng, and J. J. Green. Biomimetic tolerogenic artificial antigen presenting cells for regulatory T cell induction. Acta Biomater. 112:136\u2013148, 2020. https:\/\/doi.org\/10.1016\/j.actbio.2020.06.004.","journal-title":"Acta Biomater."},{"key":"4278_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202203163","author":"J Chen","year":"2023","unstructured":"Chen, J., S. Agrawal, H. Yi, D. Vallejo, A. Agrawal, and A. P. Lee. Cell-sized lipid vesicles as artificial antigen-presenting cells for antigen-specific T cell activation. Adv. Healthc. Mater. 2023. https:\/\/doi.org\/10.1002\/adhm.202203163.","journal-title":"Adv. Healthc. Mater."},{"key":"4278_CR23","doi-asserted-by":"publisher","first-page":"18091","DOI":"10.1074\/jbc.M117.797613","volume":"292","author":"BX Wu","year":"2017","unstructured":"Wu, B. X., A. Li, L. Lei, S. Kaneko, C. Wallace, X. Li, and Z. Li. Glycoprotein a repetitions predominant (GARP) positively regulates transforming growth factor (TGF) \u03b23 and is essential for Mouse Palatogenesis. J. Biol. Chem. 292:18091\u201318097, 2017. https:\/\/doi.org\/10.1074\/jbc.M117.797613.","journal-title":"J. Biol. Chem."},{"key":"4278_CR24","doi-asserted-by":"publisher","first-page":"42826","DOI":"10.18632\/oncotarget.8753","volume":"7","author":"L Sun","year":"2016","unstructured":"Sun, L., H. Jin, and H. Li. Garp: a surface molecule of regulatory T cells that is involved in the regulatory function and TGF-\u03b2 releasing. Oncotarget. 7:42826\u201342836, 2016. https:\/\/doi.org\/10.18632\/oncotarget.8753.","journal-title":"Oncotarget."},{"key":"4278_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0570-z","author":"A Metelli","year":"2018","unstructured":"Metelli, A., M. Salem, C. H. Wallace, B. X. Wu, A. Li, X. Li, and Z. Li. Immunoregulatory functions and the therapeutic implications of Garp-TGF-\u03b2 in inflammation and cancer. J. Hematol. Oncol. 2018. https:\/\/doi.org\/10.1186\/s13045-018-0570-z.","journal-title":"J. Hematol. Oncol."},{"key":"4278_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.29245\/2578-2967\/2019\/1.1164","volume":"3","author":"M Guo","year":"2019","unstructured":"Guo, M., W. Wu, W. Liu, and F. Ren. Mini-review: garp, a putative potential molecule in tumor immunosuppressive environment. J. Cancer Treatment Diagn. 3:14\u201318, 2019.","journal-title":"J. Cancer Treatment Diagn."},{"key":"4278_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1142\/S233954781750011X","volume":"05","author":"D Vallejo","year":"2017","unstructured":"Vallejo, D., S. H. Lee, D. Lee, C. Zhang, C. Rapier, S. D. Chessler, and A. P. Lee. Cell-sized lipid vesicles for cell-cell synaptic therapies. Technology. 05:201\u2013213, 2017. https:\/\/doi.org\/10.1142\/S233954781750011X.","journal-title":"Technology."},{"key":"4278_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101740","volume":"3","author":"J Gu","year":"2022","unstructured":"Gu, J., Q. Shao, J. Zhou, Q. Chen, and L. Lu. Protocol for in vitro isolation, induction, expansion, and determination of human natural regulatory T cells and induced regulatory T cells. STAR Protoc.3:101740, 2022. https:\/\/doi.org\/10.1016\/j.xpro.2022.101740.","journal-title":"STAR Protoc."},{"key":"4278_CR29","doi-asserted-by":"publisher","first-page":"28621","DOI":"10.18632\/oncotarget.5765","volume":"6","author":"S Agrawal","year":"2015","unstructured":"Agrawal, S., S. Ganguly, P. Hajian, J.-N. Cao, and A. Agrawal. PDGF upregulates CLEC-2 to induce T regulatory cells. Oncotarget. 6:28621\u201328632, 2015. https:\/\/doi.org\/10.18632\/oncotarget.5765.","journal-title":"Oncotarget"},{"key":"4278_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1039\/b715524g","volume":"8","author":"S-Y Teh","year":"2008","unstructured":"Teh, S.-Y., R. Lin, L.-H. Hung, and A. P. Lee. Droplet microfluidics. Lab Chip. 8:198, 2008. https:\/\/doi.org\/10.1039\/b715524g.","journal-title":"Lab Chip."},{"key":"4278_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1749-6632.1991.tb33436.x","volume":"636","author":"KB Urdahl","year":"1991","unstructured":"Urdahl, K. B., M. K. Jenkins, and S. D. Norton. Accessory cell-derived costimulatory signals regulate T cell proliferationa. Ann. N. Y. Acad. Sci. 636:33\u201342, 1991. https:\/\/doi.org\/10.1111\/j.1749-6632.1991.tb33436.x.","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"4278_CR32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten, J. H., Y. A. Helou, G. Chopra, A. Weiss, and J. A. Bluestone. CD28 costimulation: from mechanism to therapy. Immunity. 44:973\u2013988, 2016. https:\/\/doi.org\/10.1016\/j.immuni.2016.04.020.","journal-title":"Immunity."},{"key":"4278_CR33","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1086\/507309","volume":"194","author":"KM Neuzil","year":"2006","unstructured":"Neuzil, K. M., L. A. Jackson, J. Nelson, A. Klimov, N. Cox, C. B. Bridges, J. Dunn, F. DeStefano, and D. Shay. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5\u20138-year-old children. J. Infect. Dis. 194:1032\u20131039, 2006. https:\/\/doi.org\/10.1086\/507309.","journal-title":"J. Infect. Dis."},{"key":"4278_CR34","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.3390\/cells10102541","volume":"10","author":"E Piano Mortari","year":"2021","unstructured":"Piano Mortari, E., et al. Highly specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IGA. Cells. 10:2541, 2021. https:\/\/doi.org\/10.3390\/cells10102541.","journal-title":"Cells."},{"key":"4278_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01048","author":"EM Shevach","year":"2018","unstructured":"Shevach, E. M. Foxp3+ t regulatory cells: still many unanswered questions\u2014a perspective after 20 years of study. Front. Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.01048.","journal-title":"Front. Immunol."},{"key":"4278_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024590","author":"L Lu","year":"2011","unstructured":"Lu, L., J. Ma, Z. Li, Q. Lan, M. Chen, Y. Liu, Z. Xia, J. Wang, Y. Han, W. Shi, V. Quesniaux, B. Ryffel, D. Brand, B. Li, Z. Liu, and S. G. Zheng. All-trans retinoic acid promotes TGF-\u03b2-induced Tregs via histone modification but not DNA demethylation on Foxp3 gene locus. PLoS ONE. 2011. https:\/\/doi.org\/10.1371\/journal.pone.0024590.","journal-title":"PLoS ONE."},{"key":"4278_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712870","author":"I Serr","year":"2021","unstructured":"Serr, I., F. Drost, B. Schubert, and C. Daniel. Antigen-specific TREG therapy in type 1 diabetes\u2014challenges and opportunities. Front. Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.712870.","journal-title":"Front. Immunol."},{"key":"4278_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102761","volume":"20","author":"Z Mukhatayev","year":"2021","unstructured":"Mukhatayev, Z., Y. O. Ostapchuk, D. Fang, and I. C. Le Poole. Engineered antigen-specific regulatory T cells for autoimmune skin conditions. Autoimmun. Rev.20:102761, 2021. https:\/\/doi.org\/10.1016\/j.autrev.2021.102761.","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"4278_CR39","first-page":"1032","volume":"51","author":"M Zhang","year":"2016","unstructured":"Zhang, M., D.-F. Jia, and Y. Diao. Risk and solutions to chimeric antigen receptor-engineered T cell-based cancer immunotherapy. Acta Pharm. Sin. 51(7):1032\u20131038, 2016.","journal-title":"Acta Pharm. Sin."},{"key":"4278_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ymthe.2019.03.012","volume":"27","author":"R Mhaidly","year":"2019","unstructured":"Mhaidly, R., and E. Verhoeyen. The future: in vivo car T cell gene therapy. Mol. Ther. 27:707\u2013709, 2019. https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.012.","journal-title":"Mol. Ther."}],"container-title":["Annals of Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10439-026-04278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10439-026-04278-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10439-026-04278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:46:04Z","timestamp":1784295964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10439-026-04278-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":40,"alternative-id":["4278"],"URL":"https:\/\/doi.org\/10.1007\/s10439-026-04278-4","relation":{},"ISSN":["0090-6964","1573-9686"],"issn-type":[{"value":"0090-6964","type":"print"},{"value":"1573-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests relevant to this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}